#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14522	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2606	683.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1787	1787	C	911	C,A	910,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	14522	16S	1529	1529	100.0	16S.l6.c30.ctg.1	2606	683.4	0	HET	.	.	.	C207T,G,A	.	207	207	C	810	810	C	825	C,T,G,A	641,182,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4014	773.6	0	.	n	.	0	T695C	SNP	695	695	T	1216	1216	C	923	C,A,T,G	918,2,1,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4014	773.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1858	1858	A	1003	A	1003	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4014	773.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2492	2492	C	839	C,T,G	837,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4014	773.6	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3118	3118	T	869	T,C	868,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	24934	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4014	773.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2566	2566	A	755	A,C	753,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	2144	folP	852	852	100.0	folP.l15.c4.ctg.1	1939	137.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1161	1163	AGC	227;227;227	A;G,C;C	227;226,1;227	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5250	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3855	169.6	1	SNP	p	S91F	0	.	.	271	273	TCC	779	781	TCC	185;182;182	T,A;C;C	184,1;182;182	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5250	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3855	169.6	1	SNP	p	D95G	0	.	.	283	285	GAC	791	793	GAC	185;187;186	G,A;A,C;C	184,1;186,1;186	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5250	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3855	169.6	1	SNP	p	D95N	0	.	.	283	285	GAC	791	793	GAC	185;187;186	G,A;A,C;C	184,1;186,1;186	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	2002	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1777	140.5	1	SNP	p	G45D	1	.	.	133	135	GAC	721	723	GAC	219;219;219	G;A;C	219;219;219	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1100	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1503	91.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5176	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3465	186.0	1	SNP	p	D86N	0	.	.	256	258	GAC	830	832	GAC	233;234;234	G,A;A,C;C,G	232,1;233,1;233,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5176	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3465	186.0	1	SNP	p	S87R	0	.	.	259	261	AGT	833	835	AGT	230;231;232	A;G;T	230;231;232	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5176	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3465	186.0	1	SNP	p	S87W	0	.	.	259	261	AGT	833	835	AGT	230;231;232	A;G;T	230;231;232	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5176	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3465	186.0	1	SNP	p	S87I	0	.	.	259	261	AGT	833	835	AGT	230;231;232	A;G;T	230;231;232	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5176	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3465	186.0	1	SNP	p	S88P	0	.	.	262	264	TCC	836	838	TCC	230;227;226	T;C,A;C,A	230;226,1;225,1	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4234	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3157	167.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1779	1781	GGC	222;219;216	G;G;C	222;219;216	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1529	1531	GCA	252;254;254	G,T;C,G;A,G	251,1;253,1;253,1	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1532	1534	ATC	256;255;257	A;T;C,G	256;255;256,1	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1544	1546	GTG	247;249;250	G;T,A;G	247;248,1;250	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1544	1546	GTG	247;249;250	G;T,A;G	247;248,1;250	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2048	2050	ACC	217;216;218	A;C,A;C	217;215,1;218	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2102	2104	GCG	202;204;205	G;C,G;G	202;203,1;205	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2102	2104	GCG	202;204;205	G;C,G;G	202;203,1;205	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2225	2227	GGC	237;238;233	G;G;C	237;238;233	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2234	2236	GGC	235;235;237	G;G;C,T	235;235;236,1	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3976	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2907	170.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2252	2254	CCG	239;241;242	C,T,G,A;C;G	236,1,1,1;241;242	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5640	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3528	199.2	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2612	porA	1146	1146	99.83	porA.l15.c4.ctg.1	2269	143.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	766	766	C	210	C	210	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	268	90.07	porB1a.l6.c30.ctg.1	1021	27.6	0	.	p	.	0	H217N	NONSYN	649	651	CAT	778	780	AAT	5;4;3	A;A;T	5;4;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	268	90.07	porB1a.l6.c30.ctg.1	1021	27.6	0	.	p	.	0	D218N	NONSYN	652	654	GAT	781	783	AAT	3;3;3	A;A;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	268	90.07	porB1a.l6.c30.ctg.1	1021	27.6	0	.	p	.	0	A222V	NONSYN	664	666	GCT	793	795	GTT	3;3;3	G;T;T	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	268	90.07	porB1a.l6.c30.ctg.1	1021	27.6	0	.	p	.	0	V226A	NONSYN	676	678	GTA	805	807	GCA	4;4;4	G;C;A	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	268	90.07	porB1a.l6.c30.ctg.1	1021	27.6	0	.	p	.	0	.	MULTIPLE	700	702	ACT	828	830	GTA	3;3;3	G;T;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	292	porB1a	984	268	90.07	porB1a.l6.c30.ctg.1	1021	27.6	0	.	p	.	0	N237fs	FSHIFT	709	709	A	837	837	A	3	A	3	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	G38E	NONSYN	112	114	GGA	398	400	GAA	234;235;233	G;A;A	234;235;233	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	S46G	NONSYN	136	138	AGC	422	424	GGC	242;246;245	G;G;C,T	242;246;244,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	E48G	NONSYN	142	144	GAA	428	430	GGA	242;240;243	G;G;A,C	242;240;242,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	T87A	NONSYN	259	261	ACT	545	547	GCT	194;195;195	G;C;T	194;195;195	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	T89S	NONSYN	265	267	ACC	551	553	AGC	195;197;197	A;G;C	195;197;197	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	.	MULTIPLE	358	359	AA	643	644	CG	201;201	C,A;G	200,1;201	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	.	MULTIPLE	361	362	GA	646	648	CAG	202;205;205	C,A;A;G	201,1;205;205	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	N122K	NONSYN	364	366	AAC	650	652	AAA	205;208;210	A,G;A;A	204,1;208;210	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	K143E	NONSYN	427	429	AAA	713	715	GAA	227;230;230	G;A,T,C;A	227;228,1,1;230	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	V151A	NONSYN	451	453	GTA	737	739	GCA	242;242;244	G,A;C;A,C	241,1;242;242,2	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	A215T	NONSYN	643	645	GCT	929	931	ACT	244;245;243	A;C,A;T,A	244;244,1;242,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	I218M	NONSYN	652	654	ATA	938	940	ATG	238;241;241	A;T;G	238;241;241	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1052	1054	GCA	222;221;222	G;C;A	222;221;222	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1055	1057	ACG	220;222;220	A;C;G	220;222;220	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	S258G	NONSYN	772	774	AGT	1058	1060	GGG	222;227;221	G;G;G	222;227;221	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1061	1063	GTT	220;219;220	G;T,C;T	220;218,1;220	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1121	1123	GTA	237;238;238	G,T;T;A	236,1;238;238	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1160	1162	ACT	221;219;217	A;C;T	221;219;217	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1166	1168	GAT	225;227;228	G;A;T,G	225;227;227,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1178	1180	CAC	244;246;250	C;A,G;C	244;245,1;250	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	1	SNP	p	G120K	1	.	.	358	360	AAG	643	645	CGG	201;201;200	C,A;G;G	200,1;201;200	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	1	SNP	p	A121D	1	.	.	361	363	GAC	646	649	CGC	202;205;206	C,A;G;C,T	201,1;205;205,1	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2700	porB1b	1047	1047	97.04	porB1b.l15.c30.ctg.1	1503	215.9	1	SNP	p	D121N	0	.	.	361	363	GAC	646	649	CGC	202;205;206	C,A;G;C,T	201,1;205;205,1	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9382	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	5325	219.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2215	2217	AAT	238;236;236	A;A,T;T,G,A	238;235,1;234,1,1	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1424	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1316	133.8	1	SNP	p	V57M	1	.	.	169	171	ATG	640	642	ATG	251;251;249	A,G;T,G;G	250,1;250,1;249	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
